Total Payments
$149,986
2024 Payments
$16.14
Companies
24
Transactions
571
Medicare Patients
6,405
Medicare Billing
$740,964
Payment Breakdown by Category
Other$123,862 (82.6%)
Travel$15,441 (10.3%)
Food & Beverage$10,601 (7.1%)
Education$82.37 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $123,862 | 42 | 82.6% |
| Travel and Lodging | $15,441 | 79 | 10.3% |
| Food and Beverage | $10,601 | 442 | 7.1% |
| Education | $82.37 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $76,379 | 98 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $20,000 | 67 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $16,747 | 29 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $11,343 | 23 | $0 (2021) |
| Medtronic Vascular, Inc. | $10,006 | 62 | $0 (2020) |
| Esperion Therapeutics, Inc. | $9,717 | 18 | $0 (2023) |
| Medicure Pharma Inc. | $1,697 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $1,131 | 92 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $949.79 | 69 | $0 (2022) |
| Abbott Laboratories | $445.63 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16.14 | 1 | Novartis Pharmaceuticals Corporation ($16.14) |
| 2023 | $583.75 | 34 | Novartis Pharmaceuticals Corporation ($169.02) |
| 2022 | $764.89 | 52 | E.R. Squibb & Sons, L.L.C. ($233.22) |
| 2021 | $10,501 | 73 | Esperion Therapeutics, Inc. ($9,635) |
| 2020 | $13,999 | 82 | Amarin Pharma Inc. ($10,973) |
| 2019 | $36,380 | 123 | Amarin Pharma Inc. ($20,205) |
| 2018 | $34,930 | 90 | Amarin Pharma Inc. ($18,828) |
| 2017 | $52,813 | 116 | Amarin Pharma Inc. ($26,373) |
All Payment Transactions
571 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/27/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.21 | General |
| 10/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/07/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/14/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/14/2023 | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA (Device) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: Transcatheter Heart Valves | ||||||
| 08/07/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: DIABETES | ||||||
| 07/24/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/10/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/03/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/26/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/23/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $8.97 | General |
| Category: Cardiovascular | ||||||
| 06/12/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/17/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.24 | General |
| Category: Cardiovascular | ||||||
| 05/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: DIABETES | ||||||
| 05/03/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/25/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.46 | General |
| Category: Cardiovascular | ||||||
| 04/18/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.68 | General |
| Category: Cardiovascular | ||||||
| 03/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $2.40 | General |
| 03/27/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/22/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.68 | General |
| Category: Cardiovascular | ||||||
| 03/20/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,534 | 2,439 | $1.5M | $178,458 |
| 2022 | 14 | 1,782 | 2,757 | $1.8M | $213,147 |
| 2021 | 14 | 1,567 | 2,228 | $1.4M | $178,196 |
| 2020 | 15 | 1,522 | 2,478 | $514,216 | $171,163 |
Total Patients
6,405
Total Services
9,902
Medicare Billing
$740,964
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 530 | 961 | $803,103 | $92,804 | 11.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 123 | 123 | $163,103 | $21,085 | 12.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 149 | 305 | $143,262 | $20,686 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 52 | 66 | $78,467 | $10,203 | 13.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 54 | $66,365 | $8,070 | 12.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 46 | 184 | $86,000 | $7,725 | 9.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 413 | 445 | $43,329 | $4,989 | 11.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 91 | 92 | $43,250 | $4,774 | 11.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 33 | $31,526 | $3,416 | 10.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 21 | 21 | $27,054 | $3,361 | 12.4% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 40 | 155 | $11,672 | $1,344 | 11.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 553 | 1,007 | $850,329 | $100,216 | 11.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 231 | 231 | $319,893 | $40,495 | 12.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 79 | 316 | $122,412 | $14,540 | 11.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 101 | 214 | $96,728 | $13,166 | 13.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 59 | 59 | $102,698 | $10,681 | 10.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 157 | 162 | $77,988 | $8,671 | 11.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 437 | 469 | $45,138 | $5,279 | 11.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 24 | $30,120 | $4,139 | 13.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2022 | 16 | 16 | $30,279 | $3,806 | 12.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 35 | $22,715 | $3,115 | 13.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $29,565 | $2,961 | 10.0% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2022 | 14 | 15 | $7,280 | $2,636 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 13 | $15,392 | $1,897 | 12.3% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2022 | 49 | 169 | $12,506 | $1,545 | 12.4% |
About Dr. Jack Stroh, M.D
Dr. Jack Stroh, M.D is a Cardiovascular Disease healthcare provider based in Somerset, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1356347066.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Stroh, M.D has received a total of $149,986 in payments from pharmaceutical and medical device companies, with $16.14 received in 2024. These payments were reported across 571 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($123,862).
As a Medicare-enrolled provider, Stroh has provided services to 6,405 Medicare beneficiaries, totaling 9,902 services with total Medicare billing of $740,964. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Somerset, NJ
- Active Since 06/27/2005
- Last Updated 03/13/2017
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1356347066
Products in Payments
- Vascepa (Drug) $76,379
- ENTRESTO (Drug) $19,846
- PRALUENT (Drug) $16,661
- Resolute (Device) $9,888
- NEXLIZET (Drug) $7,639
- PRALUENT ALIROCUMAB INJECTION (Biological) $6,167
- PRALUENT (Biological) $5,176
- NEXLETOL (Drug) $2,079
- Aggrastat (tirofiban HCl) (Drug) $1,697
- ELIQUIS (Drug) $1,374
- XARELTO (Drug) $949.79
- Optis Coronary Imaging System (Device) $289.56
- Impella (Device) $203.31
- VERQUVO (Drug) $196.42
- BRILINTA (Drug) $169.48
- PressureWire FFR (Device) $156.07
- LEQVIO (Drug) $154.16
- GENERAL THERAPIES (Device) $139.49
- Corlanor (Drug) $128.92
- JARDIANCE (Drug) $120.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Somerset
Dr. Genevieve Everett-Sigwalt, M.d, M.D
Cardiovascular Disease — Payments: $17,807
Cardiovascular Disease $17,807
Natarajan Thannoli, Md, MD
Cardiovascular Disease — Payments: $10,564
Cardiovascular Disease $10,564
George Bou Samra, M.d, M.D
Cardiovascular Disease — Payments: $8,135
Cardiovascular Disease $8,135
Mrs. Ginger Combs, Arnp Rn, ARNP RN
Cardiovascular Disease — Payments: $2,051
Cardiovascular Disease $2,051
Jennifer Wellings, M.d, M.D
Cardiovascular Disease — Payments: $1,965
Cardiovascular Disease $1,965
Diwata Somera, Aprn-Bc, APRN-BC
Cardiovascular Disease — Payments: $1,096
Cardiovascular Disease $1,096